Key Points Johnson & Johnson announced plans to spin off its orthopedics business in late 2025. In early 2026, J&J was reported to be in talks with private equity firms about a sale. In late 2026, J&J was reported to be in talks with Apollo on a $20 billion deal. 10 stocks we like better than Johnson & Johnson › Wall Street goes through cycles in which companies buy assets to create diversified conglomerates, and then sell assets to streamline and focus. Right now, investors are rewarding companies for simplifying their operations and focusing their businesses. That's what Johnson & Johnson (NYSE: JNJ) has been doing. Here's what's been happening, why it's happening, and what it could mean for investors.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.